Cargando…
The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF). We prospectively enrolled patients with HFrEF‐induced PH admitted to the Depar...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297686/ https://www.ncbi.nlm.nih.gov/pubmed/35874853 http://dx.doi.org/10.1002/pul2.12034 |
_version_ | 1784750527718883328 |
---|---|
author | Zhao, Ying Tian, Li‐guo Zhang, Li‐xin Ma, Tao Di, Liang Wang, Yan‐bo Gu, Xin‐shun Wang, Dan‐dan Gao, Shang Wang, Haiyan |
author_facet | Zhao, Ying Tian, Li‐guo Zhang, Li‐xin Ma, Tao Di, Liang Wang, Yan‐bo Gu, Xin‐shun Wang, Dan‐dan Gao, Shang Wang, Haiyan |
author_sort | Zhao, Ying |
collection | PubMed |
description | The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF). We prospectively enrolled patients with HFrEF‐induced PH admitted to the Department of Cardiology between August 2018 and December 2019. Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril. Epidemiological data were recorded before treatment. Echocardiography was performed at admission and 6 months of follow‐up, and all parameters were compared. Major adverse cardiac events (MACEs) were compared between baseline and 6 months follow‐up. There were no significant differences in the baseline characteristics between the two groups. After 6 months of treatment, both treatment groups improved the following parameters from baseline (mean ± SD): left atrium, left ventricle, the left ventricular ejection function (LVEF), RV systolic function (the tricuspid annular plane systolic excursion [TAPSE], the systolic pulmonary artery pressure [sPAP], and TAPSE/sPAP). After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all p < 0.05): LVEF (47.07 ± 6.93% vs. 43.47 ± 7.95%); TAPSE (15.33 ± 1.31 vs. 14.78 ± 1.36 mm); sPAP (36.76 ± 14.32 vs. 42.26 ± 12.07 mmHg); and TAPSE/sPAP ratio (0.50 ± 0.23 vs. 0.39 ± 0.14), respectively. There was no difference in readmissions due to recurrent heart failure. Sacubitril/valsartan seems to provide more beneficial effects among patients with HFrEF‐induced PH to improve RV function, along with a decrease in pulmonary pressure. |
format | Online Article Text |
id | pubmed-9297686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92976862022-07-22 The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction Zhao, Ying Tian, Li‐guo Zhang, Li‐xin Ma, Tao Di, Liang Wang, Yan‐bo Gu, Xin‐shun Wang, Dan‐dan Gao, Shang Wang, Haiyan Pulm Circ Research Articles The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF). We prospectively enrolled patients with HFrEF‐induced PH admitted to the Department of Cardiology between August 2018 and December 2019. Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril. Epidemiological data were recorded before treatment. Echocardiography was performed at admission and 6 months of follow‐up, and all parameters were compared. Major adverse cardiac events (MACEs) were compared between baseline and 6 months follow‐up. There were no significant differences in the baseline characteristics between the two groups. After 6 months of treatment, both treatment groups improved the following parameters from baseline (mean ± SD): left atrium, left ventricle, the left ventricular ejection function (LVEF), RV systolic function (the tricuspid annular plane systolic excursion [TAPSE], the systolic pulmonary artery pressure [sPAP], and TAPSE/sPAP). After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all p < 0.05): LVEF (47.07 ± 6.93% vs. 43.47 ± 7.95%); TAPSE (15.33 ± 1.31 vs. 14.78 ± 1.36 mm); sPAP (36.76 ± 14.32 vs. 42.26 ± 12.07 mmHg); and TAPSE/sPAP ratio (0.50 ± 0.23 vs. 0.39 ± 0.14), respectively. There was no difference in readmissions due to recurrent heart failure. Sacubitril/valsartan seems to provide more beneficial effects among patients with HFrEF‐induced PH to improve RV function, along with a decrease in pulmonary pressure. John Wiley and Sons Inc. 2022-07-01 /pmc/articles/PMC9297686/ /pubmed/35874853 http://dx.doi.org/10.1002/pul2.12034 Text en © 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Zhao, Ying Tian, Li‐guo Zhang, Li‐xin Ma, Tao Di, Liang Wang, Yan‐bo Gu, Xin‐shun Wang, Dan‐dan Gao, Shang Wang, Haiyan The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
title | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
title_full | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
title_fullStr | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
title_full_unstemmed | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
title_short | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
title_sort | comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297686/ https://www.ncbi.nlm.nih.gov/pubmed/35874853 http://dx.doi.org/10.1002/pul2.12034 |
work_keys_str_mv | AT zhaoying thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT tianliguo thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT zhanglixin thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT matao thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT diliang thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT wangyanbo thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT guxinshun thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT wangdandan thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT gaoshang thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT wanghaiyan thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT zhaoying comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT tianliguo comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT zhanglixin comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT matao comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT diliang comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT wangyanbo comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT guxinshun comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT wangdandan comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT gaoshang comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT wanghaiyan comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction |